Latent Tuberculosis Infection
37
1
3
21
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.1%
3 terminated out of 37 trials
87.5%
+1.0% vs benchmark
32%
12 trials in Phase 3/4
24%
5 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (37)
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection
Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients
Prospective Quality Improvement Project for High-Risk Diabetes Patients
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
Latent Tuberculosis in Type 2 Diabetes
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Clinical Trial of Mica
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
Diagnosis of Tuberculosis Infection in HIV Co-infected Children
Performance Evaluation of the VIDAS TB-IGRA Assay.
VDOT for Monitoring Adherence to LTBI Treatment
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment
Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection